Диссертация (1146667), страница 20
Текст из файла (страница 20)
Ling Z. Impacts of infection with different toxigenic Clostridium difficilestrains on faecal microbiota in children [Электронный доступ] / Ling Z., Liu X. [etal.]//ScientificReports.—2014.—4. Режим доступа www.ncbi.nlm.nih.gov/pubmed/112. Loo V. G. Host and Pathogen Factors for Clostridium difficile Infectionand Colonization / Loo V. G., Bourgault A-M. [et al.] // The New England Journalof Medicine. —2011. — Vol. 365, №18. — P. 1693-1703.113. Lowy I. Treatment with monoclonal antibodies against Clostridiumdifficile toxins / Lowy I., Molrine D., Leav B. [et al.] // N Engl J Med. — 2010. —Vol.
362. —P. 197–205.109114. Lübbert C. Clostridium Difficile Infection. Guideline-Based Diagnosisand Treatment / Lübbert C., John E., von Müller L. // Dtsch Arztebl Int. —2014. —Vol. 111. — P. 723–731.115. Lupse M. Predictors of First Recurrence in Clostridium difficileassociated Disease. A Study of 306 Patients Hospitalized in a Romanian TertiaryReferral Center/ Lupse M., Flonta M., Cioara A. [et al.] // J Gastrointestin Liver Dis.—2013. — Vol. 22, № 4. —P. 397-403.116. Lv Z. Factors associated with Clostridium difficile diarrhea in a hospitalin Beijing, China / Lv Z., Peng G.L., Su J.R.
// Brazilian Journal of Medical andBiological Research. — 2014. — Vol. 47, № 12. —P. 1085-1090.117. Makino H. Transmission of intestinal Bifidobacterium longum subsp.longum strains from mother to infant determined by multilocus sequencing typingand amplified fragment length polymorphism/ Makino H., Kushiro A, Ishikawa E.[et al.] // Appl Environ Microbiol. — 2011. — Vol. 8. — P. 43–49.118. Matsumoto K. Factors Affecting Treatment and Recurrence ofClostridium difficile Infections/ Matsumoto K., N.
Kanazawa [et al.] // Biol. Pharm.Bull. . —2014. — Vol. 37, № 11. —Р. 1811–1815.119. Maynard C.L. Reciprocal interactions of the intestinal microbiota andimmune system/ Maynard C.L., Elson C.O. [et al.] // Nature. — 2012. — Vol. 489.— P. 231–241.120. McGuckin M. A. Mucin dynamics and enteric pathogens/ McGuckin M.A., Linden, S. K. [et al.] // Nat.
Rev. Microbiol. —2011. — Vol. 9. — P. 265–278.121. Mertz D. Stronger correlation between antibiotic use and the incidence ofClostridium difficile determined by culture results instead of faecal toxin detectiononly / Mertz D., Frei R., Plagge H. [et al.] // Eur. J. Clin. Microbiol. Infect. Dis. —2010. — Vol. 29. — P. 1575–1578.110122. Metcalf D. S., Costa M. C., et al. Clostridium difficile in vegetables,Canada / Metcalf D. S., Costa M. C. [et al.] // Letters in Applied Microbiology. —2010. — Vol. 51, № 5. —P. 600–602.123. Miller A.C . Hospital Clostridium difficile infection rates and predictionof length of stay in patients without C.
difficile Infection/ Miller A.C, Polgreen L.A.,Cavanaugh J.E. // Infect Control Hosp Epidemiol. —2016. — Vol. 37, № 4. —P.404-410.124. Murphy C.R. Frequent hospital readmissions for Clostridium difficileinfection and the impact on estimates of hospital-associated C. difficile burden/Murphy C.R., Avery T.R., Dubberke E.R. [et al.] // Infect Control Hosp Epidemiol.— 2012. — Vol. 33. — P.
20–28.125. Nakayama-Imaohji H. et al. Characterization of a gene cluster forsialoglycoconjugate utilization in Bacteroides fragilis // J. Med. Invest. — 2012. —Vol. 59. —P. 79–94.126. Navaneethan U. Clostridium difficile infection is associated with worselong term outcome in patients with ulcerative colitis/ Navaneethan U., Mukewar S.,Venkatesh P.G. [et al.] // J Crohns Colitis. — 2012. — Vol. 6. —P.
330–336.127. Neuendorf M. A prospective study of two isothermal amplification assayscompared with real-time PCR, CCNA and toxigenic culture for the diagnosis ofClostridium difficile infection [Электронный доступ] / NeuendorfM.,Guadarrama-Gonzalez R. [et al.] // BMC Microbiol.— 2016.— Vol. 16. Режимдоступа https://www.ncbi.nlm.nih.gov/pubmed/128. Ng K. M.
et al. Microbiota-liberated host sugars facilitate post-antibioticexpansion of enteric pathogens.// Nature. — 2013. — Vol. 502. — P. 96–99.129. Nicolle L. E. Antimicrobial stewardship in long term care facilities: whatis effective? [Электронный доступ] //Antimicrobial Resistance and InfectionControl. —2014. —3. Режим доступа https://www.ncbi.nlm.nih.gov/pubmed/111130.
Ohland C.L. Probiotics and intestinal epithelial barrier function / OhlandC.L., Mac Naughton W. K. // Am J Physiol Gastrointest Liver Physiol. — 2010. —Vol. 298, № 6. — P. 807-812.131. Oleastro M. Outbreak of Clostridium difficile PCR ribotype 027 - therecent experience of a regional hospital [Электронный доступ] / Oleastro M.,Coelho M., [et al.] // BMC Infectious Diseases.
— 2014. —Vol. 14. Режим доступаhttps://www.ncbi.nlm.nih.gov/pubmed/132. Ouwerkerk, J. P. Glycobiome: bacteria and mucus at the epithelialinterface / Ouwerkerk J. P., W.de Vos, M., Belzer C. //Best Pract. Res. Clin.Gastroenterol. —2013. — Vol. 27. — P. 25–38.133. Pakyz A. Economic impact of Clostridium difficile infection in amultihospital cohort of academic health centers / Pakyz A, Carroll N.V, Harpe S.E[et al.] // Pharmacotherapy. — 2011. — Vol.
31. —P. 546–551134. Pardi, D. The efficacy and safety of rifaximin vs. vancomycin in thetreatment of mild to moderate C. difficile infection: a randomized double-blindactive comparator trial /D. Pardi, R. Brennan [et al.] // Gastroenterology. — 2012.— Vol. 142. — P.599-565.135. Pattani R. Probiotics for the prevention of antibiotic-associated diarrheaand Clostridium difficile infection among hospitalized patients: systematic reviewand meta-analysis / Pattani R., Palda V. A., Hwang S. W. [et al.] // Open Med.
—2013. — Vol. 7, № 2. —P. 56–67.136. Pelaseyed T. et al. The mucus and mucins of the goblet cells andenterocytes provide the first defense line of the gastrointestinal tract and interactwith the immune system// Immunol. Rev. —2014. — Vol. 260. — P. 8–20.137. Penterman J. Rapid evolution of culture-impaired bacteria duringadaptation to biofilm growth / Penterman J., Nguyen D., Anderson E. [et al.] // CellRep.
— 2014. — Vol. 6. — P. 293–300.112138. Pérez-Cobas A. E. Structural and functional changes in the gut microbiotaassociated to Clostridium difficile infection / Pérez-Cobas A. E., Artacho A., Ott S.J.[et al.] // Frontiersin Microbiology. — 2014. — Vol. 5. — e335.139. Pérez-Cobas A.E. Differential effects of antibiotic therapy on the structureand function of human gut microbiota [Электронный доступ] / Pérez-Cobas A.E.,Artacho A. [et al.] // PLoSONE. — 2013. — Vol. 8. Режим доступаwww.plosone.org140.
Pituch H. Characterization and antimicrobial susceptibility of Clostridiumdifficile strains isolated from adult patients with diarrhoea hospitalized in twouniversity hospitals in Poland, 2004- 2006/ Pituch H., Obuch-Woszczatynski P.,Wultanska D. [et al.] // J. Med. Microbiol. — 2011.
— Vol. 60, № 8. —P. 1200–1205.141. Plumbridge, J. Convergent pathways for utilization of the amino sugarsN-acetylglucosamine, N-acetylmannosamine, and N-acetylneuraminic acid byEscherichia coli/ J. Plumbridge, E. Vimr // J. Bacteriol. —1999.
— Vol. 181. — P.47–54.142. Ramos-Martínez A. Risk factors for Clostridium difficile diarrhea inpatients with inflammatory bowel disease / Ramos-Martínez A., Ortiz-Balbuena J.[et al.] //Rev Esp Enferm Dig (Madrid). —2015. — Vol. 107, №1. —P. 4-9.143. Rao K. Procalcitonin Levels Associate with Severity of Clostridiumdifficile Infection / K. Rao, S. T.
Walk, D. Micic. // Plos One. —2013. — Vol. 8,№3: e58265.144. Rappe M.S, Giovannoni S.J. The uncultured microbial majority.// AnnuRev Microbiol. —2003. — Vol. 57. —P. 369–394.145. Ratia K. Discovery of Selective Inhibitors of the Clostridium difficileDehydroquinate Dehydratase [Электронный доступ] / Ratia K., Light S. H.,Antanasijevic A. [et al.] // Plos One. —2014. —9. Режим доступа www.plosone.org113146. Rea. M.
C. et al. Clostridium difficile carriage in elderly subjects andassociated changes in the intestinal microbiota // J Clin Microbiol . —2012. — Vol.50. —P. 867–875.147. Reigadas E. Toxin B PCR cycle threshold as a predictor of poor outcomeof Clostridium difficile infection: a derivation and validation cohort study/ ReigadasE, Alcalá L, Valerio M. // J Antimicrob Chemother. —2016. — Vol. 71, № 5. —P.1380-1385.148. Ritchie M. L. A meta-analysis of probiotics efficacy for gastrointestinaldiseases [Электронный доступ] / Ritchie M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
